miRNA Synthesis Service
Overview
MicroRNAs (miRNAs) are a critical class of small, noncoding RNAs, approximately 21 nucleotides in length, that function as master regulators of gene expression at the post-transcriptional level. It is estimated that miRNAs regulate the activity of over 60% of all protein-coding genes, making them pivotal tools in understanding and treating a vast array of diseases. The ability to precisely modulate these biological pathways—either by restoring a suppressed miRNA using a miRNA mimic or by blocking a pathogenic one using a chemically stabilized miRNA inhibitor—represents a high-value strategy in nucleic acid therapeutics.
Harnessing deep engagement with nucleic acid chemistry, CD BioGlyco confers upon investigators and pharmaceutical architects miRNAs of exceptional purity, each synthesis meticulously tailored. This pursuit arises from a resolve to transcend the innate biological adversities these entities endure—their fleeting stability and reluctant passage across cellular membranes. By furnishing refined, extensively engineered, and functionally attested miRNA mimics and inhibitors, CD BioGlyco anchors every therapeutic or exploratory venture upon an immutable groundwork of scholarly precision and assured integrity.
Core Technologies
The success of a miRNA-based therapeutic relies entirely on the quality, purity, and stability of the synthetic oligonucleotide. We employ state-of-the-art solid-phase chemical synthesis methods, which allow for the incorporation of a wide range of chemical modifications with unmatched fidelity.
- Synthetic Precision
We utilize optimized phosphoramidite chemistry to construct the single-stranded RNA sequences required for both mimics (which are later annealed) and Inhibitors. This precision ensures 100% sequence accuracy across the entire length, which is crucial for specific target recognition in the cell.
- Stability and Efficacy Modifications
Synthetic miRNAs, particularly inhibitors, often require advanced chemical modification strategies to enhance their resistance to nucleases and improve cell uptake. Our service incorporates critical modifications such as 2'-O-methyl (2'-O-Me), locked nucleic acid (LNA), and phosphorothioate (PS) linkages to dramatically increase the molecule's half-life in vitro and in vivo. This chemical fortification is key to achieving effective therapeutic outcomes, especially when compared to non-protected molecules.
- Quality Control Standards
Every batch is subjected to rigorous analytical validation, including mass spectrometry (MS) for verifying molecular weight and sequence integrity, and high-performance liquid chromatography (HPLC) for confirming exceptional purity and isolation from truncated sequences.
Your Sequence, Our Expertise: Custom miRNA Synthesis
We offer a flexible service scope tailored to the diverse needs of academic research and drug development, spanning fundamental discovery to advanced preclinical models.
- Product Types
- miRNA Mimics: Double-stranded RNA for exogenous restoration of miRNA function.
- miRNA Inhibitors (Anti-miRs): Single-stranded, chemically stabilized oligonucleotides (e.g., LNA- or 2'-O-Me-modified) to sequester and silence endogenous miRNAs.
- Scale and Purity
We offer a full spectrum of synthesis scales, from g quantities for initial in vitro screening to multi-gram quantities for large-scale in vivo studies. Standard purity options include desalted, PAGE, and HPLC purification (up to 98%).
- Modifications and Conjugations
Access to a vast library of chemical modifications (e.g., 2'-F, 2'-O-MOE) and conjugations is essential for optimizing cellular uptake, stability, and tracking in complex biological systems.
Workflow
Consultation & Sequence Design
Our specialists collaborate with your team to finalize the target miRNA sequence, determine the appropriate sense/antisense strands (for mimics), and specify necessary chemical modifications and delivery formats (e.g., fluorescent labels, cholesterol conjugates).
High-Fidelity Oligonucleotide Synthesis
The single-stranded RNA oligonucleotides are synthesized using optimized solid-phase chemistry. We scale the synthesis from nmol to gram quantities to meet preclinical and clinical requirements.
Advanced Purification
The crude product is purified using proprietary HPLC and polyacrylamide gel electrophoresis (PAGE) methods, guaranteeing purity levels tailored to your application. This step is crucial for removing truncated or impure sequences that can lead to non-specific effects.
Annealing and Modification
For miRNA mimics, the highly purified sense and antisense strands are precisely annealed to form a functional double-stranded (dsRNA) molecule. Inhibitors are prepared in their final chemically modified single-stranded format. Functional group conjugation (e.g., fluorophore addition) is performed at this stage.
Final Quality Assurance & Formulation
The final product undergoes final QC (MS, HPLC) to confirm specifications. The material is then formulated (typically lyophilized) and packaged for secure, stable delivery, often maintaining stability at room temperature for extended periods.

Publication Data
Journal: Frontiers in endocrinology
DOI: 10.3389/fendo.2018.00402
IF: 4.6
Published: 2018
Results: This comprehensive review article provides a detailed overview of the biogenesis, mechanisms of action, and circulation of miRNAs, highlighting their critical role as post-transcriptional regulators of gene expression. The authors systematically describe the canonical and non-canonical pathways through which miRNAs are processed from primary transcripts into mature, functional molecules, emphasizing the key proteins involved, such as Drosha, Dicer, and Argonaute. A significant portion of the review is dedicated to explaining the sophisticated mechanisms by which miRNAs mediate gene silencing, primarily through the miRNA-induced silencing complex (miRISC), which leads to translational repression or degradation of target mRNAs. Furthermore, the article explores the dynamic nature of miRNA actions, including their subcellular compartmentalization and the factors influencing their efficiency, such as miRNA/target abundance and binding affinity. Finally, the authors summarize the emerging understanding of extracellular miRNAs, detailing their secretion, stability in biological fluids, and function as chemical messengers in cell-to-cell communication, which positions them as potential biomarkers and therapeutic targets. By synthesizing current knowledge across these domains, the review presents miRNAs as central players in a complex and dynamic regulatory network that influences a vast array of biological processes and diseases.
Applications
Infectious and Inflammatory Diseases
Using miRNA inhibitors to block host-pathogen interactions or deploying mimics to suppress chronic inflammatory pathways. The ability to inhibit inflammation and pathways like pyroptosis is a high-impact application of these molecules.
Fibrotic and Chronic Conditions
Developing therapeutics aimed at conditions characterized by excessive tissue scarring, such as lung, liver, or skin fibrosis. Specific miRNA mimics, for example, have been shown to regulate key profibrotic and inflammatory factors in these models.
Drug Target Validation
Employing mimics and inhibitors as high-specificity tools to knock down or overexpress target pathways in a cellular context, providing clear causality data for drug discovery efforts.
Gene Therapy and Delivery System Development
Synthesizing the high-payload, stable miRNA components needed for cutting-edge delivery vehicles, such as nucleic acid frameworks, liposomes, or viral vectors.
Advantages
Core Expertise in Nucleic Acid Chemistry
We possess deep expertise in nucleic acid chemistry, which forms the foundation of our services. Our team has extensive experience in oligonucleotide synthesis, enabling us to tackle the inherent challenges of RNA stability and produce high-quality, custom-synthesized miRNAs for both basic research and therapeutic development. This expertise allows for flexible and diverse custom synthesis options to meet specific research requirements.
Rigorous Quality Control and Certification
We are committed to delivering products of the highest quality and consistency. We employ advanced purification methods like HPLC/MS analysis and provide comprehensive quality control reports with our products to guarantee their purity and performance.
Comprehensive Product Portfolio for Functional Studies
Our service portfolio is designed to support the full spectrum of miRNA functional studies. We provide a complete suite of products, including highly pure miRNA mimics for gain-of-function studies and miRNA inhibitors (as well as their in vivo counterparts, agomirs and antagomirs) for loss-of-function studies. Our chemically synthesized mimics are known for their high efficiency, enabling significant overexpression and yielding reliable results in cellular assays.
Advanced Technical Support and Customization
Beyond standard products, we offer extensive customization and expert technical support. Our team provides professional guidance from project consultation and experimental design to after-sales support, ensuring a seamless research experience.
Frequently Asked Questions
Customer Review
The LNA-modified Inhibitors from CD BioGlyco were the cleanest material we have ever used. Their low endotoxin levels were crucial for our sensitive in vivo mouse model, resulting in minimal non-specific toxicity and the clearest target knockdown data we've achieved to date. Truly premium quality.
— Dr. Li, Principal Investigator, Oncology Research
The technical consultation we received during the design phase was invaluable. Their team recommended a 2'-O-Me/PS-modified mimic that drastically improved the stability and efficacy in our challenging primary cell lines. This saved us months of optimization time.
— Dr. Schmidt, Group Leader, Cardiovascular Medicine
The fluorescence-labeled miRNA mimics were perfect for tracking cellular uptake kinetics. The labeling efficiency was superb, and the functional activity of the oligo was completely preserved. CD BioGlyco provides the highest quality conjugated oligos.
— Research Associate, Senior Scientist, Inflammation and Immunology
Associated Services
Our miRNA synthesis service delivers high-quality RNA constructs, establishing the molecular foundation for therapeutic development. To translate these into effective treatments, our Therapeutic Oligonucleotide Delivery Development Service provides targeted delivery solutions, including specialized GalNAc-RNA conjugates with mono, bi, tri, and tetra-antennary structures for optimized tissue-specific uptake and therapeutic efficacy.
CD BioGlyco is dedicated to fueling the next generation of gene regulation research and therapeutics. Our state-of-the-art miRNA synthesis service delivers mimics and inhibitors with guaranteed purity, unparalleled stability through expert chemical modification, and the scalability needed for every stage of your project—from foundational in vitro screening to advanced in vivo therapeutic development. If you want to obtain the essential, high-quality molecular tools that turn biological hypotheses into validated success, contact us!
Reference
- O'Brien, J.; et al. Overview of microRNA biogenesis, mechanisms of actions, and circulation. Frontiers in endocrinology. 2018, 9: 402. (Open Access)
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform



